

Table 14.2.2/3d
Summary of BCVA Score Using ETDRS change from baseline to Week 100 (LOCF) by Visit
Full Analysis Set

Treatment Group	Visit	n	Mean	SD	Value at Visit					n	Mean	SD	Change from Baseline				
					Min	Q1	Median	Q3	Max				Min	Q1	Median	Q3	Max
Sham + PRN(N =73)	Baseline	73	48.9	14.42	20	37.0	50.0	61.0	73								
	Week 4	73	46.0	19.06	3	33.0	46.0	59.0	89	73	-2.9	11.45	-33	-9.0	-1.0	4.0	23
	Week 8	73	44.2	21.10	0	30.0	48.0	59.0	88	73	-4.7	14.33	-55	-11.0	-2.0	3.0	21
	Week 12	73	44.7	21.76	0	30.0	46.0	59.0	90	73	-4.2	15.00	-44	-15.0	-1.0	6.0	23
	Week 16	73	44.8	22.42	0	26.0	48.0	61.0	89	73	-4.1	16.87	-49	-15.0	-2.0	7.0	31
	Week 20	73	45.2	22.98	0	26.0	49.0	61.0	92	73	-3.7	17.31	-67	-15.0	0.0	9.0	25
	Week 24	73	44.8	23.84	0	26.0	50.0	61.0	94	73	-4.0	17.96	-67	-15.0	0.0	7.0	26
	Week 28	73	49.5	22.88	1	35.0	52.0	66.0	94	73	0.6	17.12	-66	-4.0	7.0	12.0	25
	Week 32	73	50.8	22.86	0	33.0	52.0	67.0	94	73	1.9	17.01	-61	-4.0	8.0	13.0	31
	Week 36	73	51.0	23.75	0	35.0	53.0	69.0	93	73	2.1	18.12	-59	-6.0	7.0	16.0	36
	Week 40	73	51.1	23.06	0	35.0	53.0	68.0	94	73	2.2	17.80	-67	-4.0	6.0	15.0	37
	Week 44	73	52.0	23.00	0	35.0	53.0	73.0	94	73	3.1	17.49	-61	-4.0	8.0	16.0	36
	Week 48	73	52.3	22.74	0	37.0	54.0	69.0	95	73	3.4	17.20	-60	-6.0	7.0	16.0	37
	Week 52	73	52.7	22.74	0	38.0	54.0	70.0	95	73	3.8	17.14	-63	-4.0	8.0	16.0	36
	Week 64	73	49.8	22.76	0	35.0	52.0	67.0	94	73	1.0	17.21	-65	-9.0	6.0	14.0	34
	Week 76	73	51.0	23.07	0	35.0	54.0	67.0	94	73	2.1	16.89	-64	-7.0	7.0	14.0	26
	Week 88	73	51.0	23.84	0	33.0	52.0	71.0	94	73	2.1	18.36	-64	-6.0	9.0	16.0	33
	Week 100	73	50.4	23.35	0	35.0	52.0	69.0	95	73	1.5	17.67	-65	-7.0	6.0	14.0	30

Note: -VTE 2Q4 – VEGF Trap-Eye (VTE) administered as 2 mg every 4 week for 24 weeks.
- LOCF = Last observation carried forward.

\\Projects\VGFT_OD_0819\Analysis_CSR\programs\TLG\t_eff_summ_BCVA.sas
11:00 Thursday, 24MAY2012

Table 14.2.2/3d
Summary of BCVA Score Using ETDRS change from baseline to Week 100 (LOCF) by Visit
Full Analysis Set

Treatment Group	Visit	n	Mean	SD	Value at Visit					n	Mean	SD	Change from Baseline				
					Min	Q1	Median	Q3	Max				Min	Q1	Median	Q3	Max
VTE 2Q4 + PRN(N=114)	Baseline	114	50.7	13.90	24	40.0	52.5	63.0	73								
	Week 4	114	63.9	13.47	25	54.0	66.5	75.0	87	114	13.2	10.97	-9	5.0	11.0	20.0	47
	Week 8	114	66.5	14.83	20	60.0	69.0	78.0	94	114	15.9	12.27	-16	7.0	15.0	22.0	56
	Week 12	114	67.3	14.83	22	60.0	70.0	78.0	92	114	16.7	12.83	-35	8.0	16.0	23.0	47
	Week 16	114	68.1	14.42	26	60.0	70.0	80.0	93	114	17.4	12.97	-31	9.0	16.0	26.0	52
	Week 20	114	67.7	15.05	25	58.0	69.5	80.0	94	114	17.0	13.33	-35	10.0	16.5	25.0	55
	Week 24	114	68.0	14.32	22	59.0	69.5	79.0	94	114	17.3	12.78	-22	10.0	16.5	25.0	53
	Week 28	114	67.1	15.28	20	58.0	69.0	79.0	93	114	16.4	13.74	-30	9.0	16.0	25.0	52
	Week 32	114	67.1	14.91	25	58.0	69.0	79.0	94	114	16.4	13.10	-22	10.0	16.0	25.0	46
	Week 36	114	66.9	16.82	0	58.0	70.0	80.0	91	114	16.2	15.63	-60	10.0	17.0	25.0	47
	Week 40	114	66.9	16.37	0	59.0	71.0	79.0	94	114	16.2	14.92	-60	11.0	16.5	24.0	54
	Week 44	114	66.7	17.24	0	58.0	71.0	79.0	93	114	16.0	15.64	-60	10.0	16.0	25.0	55
	Week 48	114	66.8	17.40	0	59.0	71.0	79.0	93	114	16.2	16.49	-60	10.0	17.0	25.0	50
	Week 52	114	66.8	18.19	0	56.0	70.5	79.0	93	114	16.2	17.35	-60	10.0	17.5	25.0	51
	Week 64	114	63.7	19.67	0	54.0	67.5	78.0	93	114	13.0	18.18	-60	6.0	15.0	25.0	52
	Week 76	114	64.8	17.95	0	55.0	67.5	78.0	92	114	14.2	15.57	-50	7.0	16.0	25.0	49
	Week 88	114	63.5	20.15	0	53.0	67.5	78.0	93	114	12.8	18.99	-50	6.0	16.0	25.0	49
	Week 100	114	63.6	19.40	0	53.0	66.0	79.0	94	114	13.0	17.72	-50	3.0	15.0	25.0	49

Note: -VTE 2Q4 – VEGF Trap-Eye (VTE) administered as 2 mg every 4 week for 24 weeks.
- LOCF = Last observation carried forward.

\\Projects\VGFT_OD_0819\Analysis_CSR\programs\TLG\t_eff_summ_BCVA.sas
11:00 Thursday, 24MAY2012